VARIANT combines innovation with reliability via VAR-002, a versatile gene therapy based on the clinically validated AAV backbone and a proven delivery route. VAR-002 outperforms competing “broad-spectrum” AAV therapies to address multiple IRDs regardless of the gene, mutation or disease.

With a large addressable market, a clear path to the clinic and solid financial roadmap, Variant is poised to bring this transformational therapy to patients for whom there are simply no other options.

VARIANT delivers a differentiated solution for a broad spectrum of inherited retinal dystrophies, while benefiting from the regulatory advantages associated with rare diseases.

With an entry valuation still significantly lower than our French and U.S. competitors, VARIANT offers a unique investment opportunity with strong value creation potential.